CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

Company Overview - CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for bladder cancer patients [6] - The company aims to enhance the quality of life for urologic cancer patients through innovative immunotherapies [6] Clinical Trials and Developments - CG Oncology will host a conference call on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy for high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) [1] - Cretostimogene is an investigational oncolytic immunotherapy being evaluated in the BOND-003 trial and is also part of another Phase 3 trial (PIVOT-006) for intermediate-risk NMIBC [4][5] - The safety and efficacy of cretostimogene have not yet been established by the FDA or any other health authority [5] Bladder Cancer Statistics - An estimated 85,000 people are expected to be diagnosed with bladder cancer in 2025, with NMIBC representing approximately 75% of newly diagnosed cases [3] - Bladder cancer is the sixth most common cancer in the United States, with men accounting for three-quarters of new diagnoses [3]